A Mar­tin Shkre­li wannabe de­fends a big spike in drug price and earns a Twit­ter lash­ing from the FDA's com­mish

There’s a broad con­sen­sus that the phar­ma in­dus­try has at least tem­porar­i­ly checked its im­pulse to keep hik­ing prices on their port­fo­lios. But a small drug­mak­er named Nos­trum Lab­o­ra­to­ries ap­pears not to have re­ceived the memo — and now the com­pa­ny is on the re­ceiv­ing end of a Twit­ter-lash­ing by FDA com­mis­sion­er Scott Got­tlieb.

Ac­cord­ing to the Fi­nan­cial Times‘ David Crow, which has been field­ing a se­ries of these sto­ries, Nos­trum hiked the price of an old an­tibi­ot­ic from $474.75 to $2,392 last month. And the CEO is proud­ly align­ing him­self with Mar­tin Shkre­li, now do­ing time in a fed­er­al prison for fraud af­ter kick­ing up an almighty storm of protest over his price goug­ing strat­e­gy with Dara­prim.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER